Li DK, et al. - This retrospective population-based cohort study was performed to examine whether direct-acting antiviral (DAA) use was correlated with higher rates of incident hepatocellular carcinoma (HCC) compared to treatment with interferon-based regimens. In cirrhotics with chronic HCV infection, DAA treatment was not associated with a higher risk of HCC in the short-term. Through both the presence of relatively fewer baseline HCC risk factors in persons treated with IFN as well as selection bias, previously reported higher rates of HCC associated with DAA treatment could be explained since DAA regimens were used to treat persons at higher risk for developing HCC.